Subtype
Malignant Urinary System Neoplasm
CI-CAN-00001187Explore in graph →
888 active trials28 approved drugs109 evidence items
- NCIt
- C9297
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001187Explore in graph →
Clinical trials
3,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (556)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04003610 | Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) | terminated | Phase 2 | 7 | Incyte CorporationINDUSTRY | 16 | Nov 4, 2025 | clinicaltrials |
| NCT04724018 | Sacituzumab Govitecan Plus EV in Metastatic UC | recruiting | Phase 1 / Phase 2 | 106 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| Avelumab and Radiation in Muscle-Invasive Bladder Cancer |
| terminated |
| Phase 2 |
| 14 |
| Dana-Farber Cancer InstituteOTHER |
| 1 |
| Oct 31, 2025 |
| clinicaltrials |
| NCT04586244 | An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma(Optimus) | terminated | Phase 2 | 30 | Incyte CorporationINDUSTRY | 3 | Oct 30, 2025 | clinicaltrials |
| NCT05564416 | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Oct 21, 2025 | clinicaltrials |
| NCT06005818 | Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)(MRD GATE RCC) | recruiting | Phase 2 | 100 | University of Alabama at BirminghamOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT07218692 | RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy | not yet recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT03022825 | QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer | active not recruiting | Phase 2 / Phase 3 | 190 | ImmunityBio, Inc.INDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT06829823 | Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | not yet recruiting | Phase 2 | 20 | ImmunityBio, Inc.INDUSTRY | 0 | Oct 16, 2025 | clinicaltrials |
| NCT03978624 | Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer | active not recruiting | Phase 2 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT05931393 | Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) | recruiting | Phase 2 | 18 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT01382706 | Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder | terminated | Phase 2 | 15 | University of Southern CaliforniaOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT03914794 | A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors | completed | Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT00722228 | Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors | recruiting | Phase 1 / Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT03438708 | Prior Axitinib as a Determinant of Outcome of Renal Surgery(PADRES) | active not recruiting | Phase 2 | 22 | University of California, San DiegoOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | terminated | Phase 2 | 23 | Day One Biopharmaceuticals, Inc.INDUSTRY | 7 | Oct 2, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05148546 | Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer(NESCIO) | active not recruiting | Phase 2 | 69 | The Netherlands Cancer InstituteOTHER | 2 | Sep 30, 2025 | clinicaltrials |
| NCT03075423 | Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC | completed | Phase 2 | 316 | Goethe UniversityOTHER | 7 | Sep 26, 2025 | clinicaltrials |
| NCT05965856 | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 52 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT04678362 | TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma(TALASUR) | recruiting | Phase 2 | 50 | Centre Francois BaclesseOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07184021 | Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer(No Acronym) | not yet recruiting | Phase 2 | 30 | Assiut UniversityOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04383743 | Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer | completed | Phase 2 | 17 | University of WashingtonOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05329532 | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer(ModiFY) | recruiting | Phase 1 / Phase 2 | 168 | Scancell LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 33 | Vyriad, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07172386 | Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC | recruiting | Phase 2 | 40 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07175480 | PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk(Perfumer) | recruiting | Phase 2 | 30 | Jinling Hospital, ChinaOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05845814 | A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) | active not recruiting | Phase 1 / Phase 2 | 390 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 10, 2025 | clinicaltrials |
| NCT00082706 | Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant | active not recruiting | Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06302569 | Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma(REPRINT) | recruiting | Phase 2 | 23 | Giuseppe ProcopioOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04758507 | Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Renal Cell Carcinoma(TACITO) | completed | Phase 1 / Phase 2 | 50 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT04887831 | Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab(PRESERVE3) | terminated | Phase 2 | 92 | G1 Therapeutics, Inc.INDUSTRY | 5 | Sep 8, 2025 | clinicaltrials |
| NCT07159191 | Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 0 | Sep 8, 2025 | clinicaltrials |
| NCT05318573 | A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 120 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT05263245 | The Pharmacological Effects of Using Cabozantinib With a Light Breakfast(Skippy 1) | completed | Phase 2 | 12 | dr. Tom van der HulleOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06255223 | A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy | recruiting | Phase 2 | 35 | Jinling Hospital, ChinaOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06571708 | Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)(NeoSTOP-IT) | recruiting | Phase 2 | 36 | Columbia UniversityOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05879653 | Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD) | recruiting | Phase 2 | 30 | Kyoto University HospitalOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT06127238 | Study of ST-1898 in Advanced Renal Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 90 | Beijing Scitech-Mq Pharmaceuticals LimitedINDUSTRY | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | recruiting | Phase 2 | 400 | Fudan UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)(GLIMMER-01) | completed | Phase 1 / Phase 2 | 69 | Palleon Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT06361810 | PSMA Therapy and Immunotherapy in Kidney Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT04936230 | Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07126119 | Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC | recruiting | Phase 2 | 35 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06983210 | Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma(GRAPE) | recruiting | Phase 2 | 43 | Nagoya UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07122414 | A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer | recruiting | Phase 1 / Phase 2 | 80 | Suzhou Forlong Biotechnology Co., LtdINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07011849 | Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 13, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06364956 | Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma | recruiting | Phase 1 / Phase 2 | 36 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 11, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 4, 2025source: clinicaltrials